



A tale of two cinnamons: a comparative review of the clinical 
evidence of Cinnamomum verum and C.cassia as diabetes 
interventions
Shinjiyo, N., Waddell, G. and Green, J.
 
NOTICE: this is the authors’ version of a work that was accepted for publication in 
Journal of Herbal Medicine. Changes resulting from the publishing process, such as 
peer review, editing, corrections, structural formatting, and other quality control 
mechanisms may not be reflected in this document. Changes may have been made to 
this work since it was submitted for publication. A definitive version was subsequently 
published in Journal of Herbal Medicine, DOI: 10.1016/j.hermed.2020.100342, 2020.
The final definitive version in Journal of Herbal Medicine is available online at:
https://dx.doi.org/10.1016/j.hermed.2020.100342
© 2020. This manuscript version is made available under the CC-BY-NC-ND 4.0 license 
https://creativecommons.org/licenses/by-nc-nd/4.0/
The WestminsterResearch online digital archive at the University of Westminster aims to make the 
research output of the University available to a wider audience. Copyright and Moral Rights remain 
with the authors and/or copyright owners.
Whilst further distribution of specific materials from within this archive is forbidden, you may freely 
distribute the URL of WestminsterResearch: ((http://westminsterresearch.wmin.ac.uk/).
In case of abuse or copyright appearing without permission e-mail repository@westminster.ac.uk
Journal Pre-proof
A tale of two cinnamons: a comparative review of the clinical evidence of
Cinnamomum verum and C. cassia as diabetes interventions




To appear in: Journal of Herbal Medicine
Received Date: 17 June 2018
Revised Date: 16 July 2019
Accepted Date: 10 February 2020
Please cite this article as: Shinjyo N, Waddell G, Green J, A tale of two cinnamons: a
comparative review of the clinical evidence of Cinnamomum verum and C. cassia as diabetes
interventions, Journal of Herbal Medicine (2020),
doi: https://doi.org/10.1016/j.hermed.2020.100342
This is a PDF ﬁle of an article that has undergone enhancements after acceptance, such as
the addition of a cover page and metadata, and formatting for readability, but it is not yet the
deﬁnitive version of record. This version will undergo additional copyediting, typesetting and
review before it is published in its ﬁnal form, but we are providing this version to give early
visibility of the article. Please note that, during the production process, errors may be
discovered which could affect the content, and all legal disclaimers that apply to the journal
pertain.
© 2019 Published by Elsevier.
Systematic Review Article 
Title:  
A tale of two cinnamons: a comparative review of the clinical evidence of Cinnamomum 
verum and C. cassia as diabetes interventions 
 
Noriko Shinjyo1,2, Guy Waddell3, and Julia Green3 
 
1. Department of Infection and Host Defence, Graduate School of Medicine, Chiba 
University, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan 
 
2. Division of Molecular and Cellular Immunoscience, Department of Biomolecular Sciences, 
Faculty of Medicine, Saga University, 5-1-1 Nabeshima, Saga 849-8501, Japan 
 
3. Department of Life Sciences, Faculty of Science and Technology at the University of 
Westminster, 115 New Cavendish Street London W1W 6UW, United Kingdom 
 





Objective: This review investigates the effectiveness of two cinnamon species, Cinnamomum 
verum and C. cassia, in diabetes management; their impact on related health conditions and 
relevant parameters in healthy individuals and safety issues.  
Methods: PubMed, Cochrane Library, and ScienceDirect were searched from 2000 up to 
April 2018 for clinical trials using either C. verum or C. cassia in controlling blood glucose 
and other diabetes-related parameters and conditions.  
Results: A total of twenty-five studies (n=997) were included for reviewing clinical evidence. 









(T2DM) patients (n=831), four investigated subjects with related clinical conditions (n=82), 
and six investigated healthy individuals (n=84). Nineteen studies used C. cassia and six used 
C. verum. Results suggested C. cassia helped manage diabetes at 3-6g, while the 
effectiveness of C. verum remained inconclusive. In addition, the chemical properties of C. 
cassia and C. verum differ considerably. Of note, C. cassia contains high levels of the 
potentially hepatotoxic constituent coumarin. A skin rash was the only adverse event 
reported.  
Conclusion: While evidence supports the therapeutic benefit of C. cassia, interchangeability 
of C. cassia and C. verum remains inconclusive. Further research is warranted to address the 
effectiveness and safety of these cinnamon species. Given the potential hepatotoxicity of C. 
cassia, RCTs that include liver function tests are required. Robust RCTs on C. verum are 
recommended to establish if its efficacy can match its safety profile.   
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1. Introduction 
The number of diabetes sufferers has been increasing. In 2014, globally, 422 million people 
were living with diabetes, compared with 108 million in 1980, according to the World Health 
Organization (WHO, 2016). Diabetes is a metabolic disorder affecting blood glucose levels, 
which can have serious consequences, including cardiovascular disease, nephropathy, 
retinopathy, peripheral neuropathy and diabetic foot (Struijs et al., 2006; WHO, 2016). The 
majority of diabetes patients are affected by type II diabetes mellitus (T2DM), which mainly 
occurs among adults and is associated with insulin resistance, metabolic syndrome and 
obesity (Kahn et al., 2006).  Growing evidence suggests the association between insulin 
resistance and several clinical conditions, including polycystic ovarian syndrome (PCOS) 
(Pauli et al., 2011), non-alcoholic fatty liver disease (NAFLD) (Ballestri et al., 2016),  various 
cancers (Malaguarnera et al., 2017; Vona-Davis et al., 2007)  and their complications (e.g.  









suggests that people with diabetes are at an increased risk for cognitive decline, vascular 
dementia, and Alzheimer’s disease (Gudala et al., 2013; Ninomiya, 2014; Ojo and Brooke, 
2015), indicating the importance of diabetes management in the ageing population.  
Due to the increasing prevalence and chronic nature, T2DM is a global health issue of 
significant economic importance. According to American Diabetes Association (ADA), the 
direct medical cost in 2012 was $176 billion in the United States, and average medical 
expenditure on a diabetes patient was about $13,700 per year: approximately 2.3 times higher 
than the estimate in the absence of diabetes (ADA, 2013). In Europe, a study comprising 8 
countries (Belgium, France, Germany, Italy, the Netherlands, Spain, Sweden and the United 
Kingdom) revealed the cost of T2DM to be € 29 billion a year (1999 values) and the 
estimated average yearly cost € 2834 per patient (Jönsson B and Board., 2002). In Germany 
alone, average annual direct cost of medical care was € 5,262, approximately 1.9 times higher 
compared with costs of age- and sex-matched non-diabetic control subjects (Köster et al., 
2006). Although some of the top-selling medications such as metformin are modestly priced 
and drug costs for managing T2DM are relatively low (7% of the total healthcare costs for 
T2DM) (Jönsson B and Board., 2002), the exploration of blood glucose management using 
traditional herbal medicines is warranted as it could help prevent the development of T2DM 
and comorbidities, thereby reducing the direct and indirect costs. Current anti-diabetic drugs 
such as sulfonylureas and -glucosidase inhibitors help manage blood glucose levels.  
However, due to potential side effects such as nausea, dyspepsia and weight gain (Sola et al., 
2015; van de Laar, 2008), it is important to find effective and safer alternatives.  
 The medicinal properties of cinnamon have been acknowledged since antiquity (De 
Vos, 2010). The genus Cinnamomum (Lauraceae) includes more than 250 species, among 
which Cinnamomum verum J.Presl (synonym: C. zeylanicum Blume, Ceylon cinnamon or 
true cinnamon) and C. cassia (L.) J.Presl (synonym: C. aromaticum Nees, cassia cinnamon or 
Chinese cinnamon) are most commonly used as medicines (Nabavi et al., 2015). The inner 








Mills, 2013; Klein and Rister, 1993). Historically, C. cassia is among the top 14 ‘simples’ 
(plants that can be used on their own for medicinal purposes, rather than as part of a formula) 
listed in 12 important texts including Hippocratic Corpus  (5th -4th century BC), De Materia 
Medica by Dioscorides (1st century AD), The Canon of Medicine (volume 2) by Avicenna 
(980 – 1037 AD), and Farmacopea Espanola (1865), while C. verum is one of the top 26 
simples, listed in 11 out of the 12 texts (De Vos, 2010). In The Canon of Medicine, 
Cinnamomum spp. was among 18 plants that protect the liver from injuries or diseases, and 
recent studies confirmed the hepatoprotective effect of Cinnamomum spp. using animal 
models (Shamsi-Baghbanan et al., 2014). In a 15th-century French herbal ‘Le Livre des 
Simples Medecines’, cinnamon was among the six medicinal spices (pepper, ginger, 
cinnamon, cloves, nutmeg, and mace). The text states that cinnamon is used ‘for weakness of 
the stomach and liver and to help digestion weakened by cold’, ‘to restore appetite’, ‘for 
recently cracked lips and other sores’, and ‘for heart ailments and syncope’ (Nam, 2014). In 
fact, the use of cinnamon to treat digestive tract ailments has continued throughout history 
(De Vos, 2010). The European Medicine Agency (EMA) endorses the traditional use of C. 
verum for symptomatic treatment of mild, spasmodic gastro-intestinal complaints (EMA, 
2011b). At present, cinnamon is on the market as a prophylactic supplement for metabolic 
syndrome, insulin resistance, T2DM, hyperlipidaemia, and arthritis (Medagama, 2015; Rafehi 
et al., 2012). 
 The major constituents of cinnamon include cinnamaldehyde, cinnamyl acetate, 
eugenol, catechin, epicatechin, and proanthocyanidins (Chen et al., 2012; Chen et al., 2014; 
Kaul et al., 2003; Vallverdú-Queralt et al., 2014). A number of potential mechanisms for 
cinnamon have been suggested (Rafehi et al., 2012), including activation of phosphorylation 
of insulin receptors -subunits; increased expression of GLUT 4, increase in GLUT 1 
mediated glucose uptake, increase in GLP-1, increase in PPAR, inhibition of intestinal -
glucosidase and pancreatic -amylase, inhibition of gluconeogenesis, and delay of gastric 









cinnamon extract and the active constituents (Medagama, 2015). In vivo studies found 
improved insulin sensitivity and lowered intestinal carbohydrate absorption after the 
treatment with cinnamon extract in T2DM model mice (Kim et al., 2006), a reduction of 
plasma glucose levels by cinnamaldehyde via insulin secretion from pancreatic -cells 
(Subash Babu et al., 2007), insulin-like activity of cinnamon polyphenols (trimers and 
tetramers of catechin and epicatechin) (Anderson et al., 2004), blood glucose-lowering effects 
of polyphenol-enriched C. verum extract (IM et al., 2014b) and polyphenol-enriched de-
coumarinated C. cassia extract (IM et al., 2014a), and lowered triglyceride and total 
cholesterol levels after treatment with cinnamon extract in T2DM model mice (Kim et al., 
2006). PPAR- and  activation in adipocytes (Sheng et al., 2008) and up-regulation of anti-
inflammatory factors such as tristetraprolin and glucose transporter (GLUT1) in macrophages 
were also suggested in vitro (Cao et al., 2008). Using C. verum, Kadan et al. demonstrated a 
significant gain in GLUT4 on the cell surface of muscle cells, suggesting that C. verum could 
facilitate glucose uptake into skeletal muscle (Kadan et al., 2013). Considering that glycemic 
fluctuations and hyperglycemia trigger endothelial dysfunction and inflammation (Mannucci 
et al., 2013), controlling hyperglycemia is likely to reduce the risk of atherogenesis and 
cardiovascular events. In addition, hyperglycemia and abnormal insulin levels are related to 
an increased risk of Alzheimer’s disease as well as vascular dementia (Gudala et al., 2013; 
Matsuzaki et al., 2010; Rönnemaa et al., 2008; Young et al., 2006). Therefore, the 
hypoglycaemic property of cinnamon may protect against diabetes-related comorbidities such 
as cardiovascular diseases and dementia.  
The EMA states that cinnamon bark contains up to 4% of essential oil consisting 
primarily of cinnamaldehyde (60-75%) (EMA, 2011a). Herbal preparations equivalent to 2-4g 
cinnamon per day, or 50-200mg of essential oil, are indicated for symptomatic treatment of 
mild spasmodic gastrointestinal complaints including bloating and flatulence (EMA, 2011b). 
C. cassia has traditional use similar to C. verum, however the two species have differences in 








contains 49.9–62.8% trans-cinnamaldehyde while C. cassia contains almost 95% 
cinnamaldehyde. In addition, it is notable that C. cassia contains coumarin up to 1% (Krieger 
et al., 2013), whereas C. verum contains coumarin only at trace or undetectable levels 
(Krieger et al., 2013; Ranasinghe et al., 2013). Considering that o-
hydroxyphenylacetaldehyde (o-HPA), a metabolite of coumarin, is hepatotoxic, long-term 
consumption of C. cassia may pose a health risk (Abraham et al., 2010; Ranasinghe et al., 
2013), while C. verum would likely be free of this particular risk (Medagama, 2015). 
Therefore it has been suggested that C. verum should be used in preference to C. cassia in 
treating T2DM (Medagama, 2015). 
 Five reviews have examined the efficacy of cinnamon species for diabetes (Table 1). 
A systematic review and meta-analysis conducted in 2012 (Leach and Kumar, 2012) assessed 
ten RCTs published between 2003 and 2010. The authors concluded that there is insufficient 
evidence to support the use of cinnamon as an anti-diabetes mellitus treatment. On the other 
hand, systematic review and meta-analysis by Akilen et al. (2012) found a significant 
decrease in HbA1c and fasting blood glucose levels (Akilen et al., 2012). A year later, In 
2013, a meta-analysis (Allen et al., 2013) found significant improvement in fasting blood 
glucose levels as well as in lipid parameters, although no significant effect was found on 
HbA1c levels. Another meta-analysis (Alanazi and Khan, 2015)  reflected the findings of 
Allen et al. (2013). Medagama (2015) found improved glycaemic control in T2DM patients 
without other medications as well as those with pre-diabetes and high pre-treatment HbA1c. 
Medagama concluded that cinnamon is potentially useful as an adjuvant therapy in managing 
T2DM. The difference in conclusions between those reviews is interesting, ranging from 
insufficient evidence to a useful add on treatment. Of note, none of these reviews separately 
assessed the different cinnamon species. Overall this suggests the evidence for effective 
intervention in T2DM is growing, but provisional, given the heterogeneity of cinnamon 
species, preparations, and dosages.   
 The herbal CONSORT statement (Gagnier et al., 2006) considers it “imperative that 









including the Latin binomial name together with botanical authority and family name in 
addition to common names for each herbal ingredient.  If the species is unspecified it is 
difficult to establish causality. Given the potential confusion, substitution or adulteration of 
herbal products, (Fong, 2002; Posadzki et al., 2012), this review focuses on interventions 
using two named cinnamon species: C. cassia and C. verum. 
 While Medagama discussed the safety issue of high coumarin content in C cassia, 
suggesting C. verum syn zeylanicum as a safer alternative, none of the five reviews evaluated 
the differential efficacy of the two main medicinal cinnamon species and their dosages as a 
T2DM intervention and whether the coumarin content of these species is a cause for concern. 
Furthermore, these reviews did not assess the differential evidence for the suitability of the 
two cinnamon species for related clinical conditions, nor the effect of the two cinnamon 
species on blood sugar related parameters in healthy populations. Hence, this study seeks to 
review the current evidence for C. cassia and C. verum in the treatment of T2DM and 
metabolically related conditions, their effects on blood sugar related parameters in healthy 
populations, and their safety profile.  
 
2. Methods 
2.1 Database searching for clinical evidence 
The current review focuses on trials investigating the effects of C. verum and C. cassia on the 
levels of blood glucose and other relevant parameters in diabetes management. To consider 
prophylactic benefits and effectiveness in the management of diabetes, trials on T2DM 
patients, as well as subjects with other related clinical conditions and healthy individuals, 
were reviewed.  
Search strategy 
To find clinical evidence for the anti-diabetic effects of C. verum and C. cassia, searches were 
conducted using databases, namely PubMed/Medline, Cochrane Library, and ScienceDirect. 
Studies were included in the current review if they were published between 2000 up to April 








article type ‘Clinical Trial’, using search terms ‘Cinnamomum verum’ and its botanical 
synonym ‘Cinnamomum zeylanicum’, ‘Cinnamomum cassia’, and its botanical synonym 
‘Cinnamomum aromaticum’. The same terms were used for searching in Cochrane Library, 
and ScienceDirect. For ScienceDirect, searches were refined by selecting ‘Abstract, Title, 
Keywords’ and categories of ‘Nursing and Dentistry’, ‘Nursing and Health Professions’, 
‘Pharmacology’, and ‘Toxicology and Pharmaceutical Science’.  
Inclusion criteria: 
1. Original study  
2. Focusing on the effect of either C. verum or C. cassia (not in combination with 
other herbs or nutrients) in controlling blood glucose levels or other parameters 
relevant to diabetes management or related clinical conditions 
 3. Published in English 
 4. Controlled 
Publications not meeting the above criteria, as well as studies using unspecified or different 
cinnamon species, or combination products, were excluded.  Each author assessed the final 
selection of studies independently, before final agreement on inclusion. 
 
2.2 Coumarin content and safety issues 
To assess coumarin contents and potential toxicity of cinnamon species, database searches 
were conducted for journal articles using the combination of 2 keywords, namely coumarin 
and either C. verum or C. cassia. PubMed searches were conducted using the following 
search terms: (1) (Cinnamomum zeylanicum) AND coumarin, (2) (Cinnamomum verum) 
AND coumarin, (3) (Cinnamomum cassia) AND coumarin, and (4) (Cinnamomum 
aromaticum) AND coumarin, for publication from 1971 to November 2017. For 
ScienceDirect, the same term combinations were searched in abstract, title, and keywords. 
Searches were conducted on 2017 Dec 1-3. Papers were screened by title and abstract, and 
then selected for reviewing if it contained quantitative information about the contents of 










3. Results and Discussions 
There are 3 most common ways to detect diabetic and prediabetic conditions: fasting blood 
glucose, HbA1c levels, and glucose tolerance (ADA, 2010; Patel and Macerollo, 2010). 
HbA1c test is a blood test that provides the average blood glucose over the past 3 months. 
Oral Glucose Tolerance Test (OGTT) measures glucose tolerance by measuring blood 
glucose after fasting and after glucose intake. Trials reviewed in this study assessed the 
effectiveness of cinnamon in T2DM patients using these and related parameters, as well as 
the effect of C. cassia and C. verum on related conditions and healthy populations.  
 
3.1 Cinnamon for diabetes management 
A total of 12 database searches (4 for each database: PubMed, ScienceDirect, and Cochrane 
Library) were conducted using the 4 search terms, and 308 results were obtained. There were 
67 results (39 from PubMed, 21 from ScienceDirect, and 7 from Cochrane Library) for 
‘Cinnamomum verum, 121 results (38 from PubMed, 37 from ScienceDirect, and 46 from 
Cochrane Library) for ‘Cinnamomum zeylanicum’, 100 results (10 from PubMed, 78 from 
ScienceDirect, and 12 from Cochrane Library) for ‘Cinnamomum cassia’, and 20 results (7 
from PubMed, 6 from ScienceDirect, and 7 from Cochrane Library) for ‘Cinnamomum 
aromaticum’. After removing duplicates and screening from title and abstract, 32 articles 
remained. Seven studies were removed, three due to the lack of information on the cinnamon 
species used in the trials (Altschuler et al., 2007; Khan et al., 2010; Mirfeizi et al., 2016); 
three using a different species: C.burmanii as the formulation CinSulin (Anderson et al., 
2016; Roussel et al., 2009; Ziegenfuss et al., 2006); one using a combination product 
including zinc gluconate (Wainstein et al., 2011). The remaining 25 studies of 997 
participants were selected for reviewing (Table 1).  The selection process is presented in a 
flowchart (Figure 1).  
 Fifteen studies were conducted on T2DM patients, among which twelve trials used C. 








Hasanzade et al., 2013; Khan et al., 2003; Lu et al., 2012; Mang et al., 2006; Sengsuk et al., 
2016; Soni and Bhatnagar, 2009; Suppapitiporn et al., 2006; Vanschoonbeek et al., 2006)  
(n=730) and three trials used C. verum (Azimi et al., 2014; Azimi et al., 2016; Vafa et al., 
2012) (n=123).  Dosages were 1-3g per day, and durations of the trials ranged from 30 days to 
four months. Reduction in fasting blood glucose or other diabetes-related parameters were 
demonstrated in ten studies (C. cassia 1.5-6g per day for 40 days - four months, or C. verum 
3g per day for 8 weeks) (Akilen et al., 2010; Azimi et al., 2014; Azimi et al., 2016; Crawford, 
2009; Gullapalli et al., 2013; Khan et al., 2003; Lu et al., 2012; Mang et al., 2006; Sengsuk et 
al., 2016; Soni and Bhatnagar, 2009), and a study showed postprandial blood glucose 
decrease after 40-day administration of C. cassia (2g per day) (Soni and Bhatnagar, 2009). 
On the other hand, four studies found no significant effect on fasting blood glucose levels 
after 1-1.5g C. cassia administration for 30 days – three months (Blevins et al., 2007; 
Hasanzade et al., 2013; Suppapitiporn et al., 2006; Vanschoonbeek et al., 2006). Four studies 
(n=82) were conducted on subjects with other clinical conditions such as impaired glucose 
tolerance (IGT), high fasting or postload blood glucose levels and obesity. Among these 
studies, three trials used C. cassia (Gutierrez et al., 2016; Magistrelli and Chezem, 2012; 
Wickenberg et al., 2014) (n=72) and one trial used C. verum (Wickenberg et al., 2012) 
(n=10). Three trials were conducted on postprandial glucose levels using an oral glucose 
tolerance test with cinnamon intake at the test (Gutierrez et al., 2016; Wickenberg et al., 
2012; Magistrelli and Chezem, 2012). Intake of C. cassia 5-6g reduced postprandial glucose 
levels in obese individuals (Gutierrez et al., 2016; Magistrelli and Chezem, 2012), while C. 
verum 6g had no effect in IGT patients (Wickenberg et al., 2012). Twelve-week oral 
administration of 12g of C. cassia had no effect on insulin sensitivity, fasting blood glucose 
or HbA1c (Wickenberg et al., 2014). Six studies were conducted on 84 healthy subjects, 
among which four trials used C. cassia (Hlebowicz et al., 2009; Mettler et al., 2009; Solomon 
and Blannin, 2007, 2009) and two trials used C. verum (Beejmohun et al., 2014; Markey et 
al., 2011). Five OGTT studies were conducted with C. cassia or C. verum (Beejmohun et al., 








2007) and one study looked at postprandial glucose and insulin levels after 14-day 
administration of C. cassia (Solomon and Blannin, 2009). Positive outcomes were obtained in 
the trials using C. cassia (3-5g) (Hlebowicz et al., 2009; Mettler et al., 2009; Solomon and 
Blannin, 2007, 2009), and 1g alcoholic extract of C. verum (Beejmohun et al., 2014). 
However, C. verum 3g had no effect on postprandial glucose and lipid levels after a high fat 
meal (Markey et al., 2011). 
 
3.1.1 T2DM: C. cassia and C. verum compared (Table 2-1)  
Out of 15 studies on T2DM patients, 12 used C. cassia and three used C. verum. Of these 15 
studies, ten reported significant improvements with a variety of outcome measures including 
HbA1c, fasting blood glucose, postprandial blood glucose and insulin as well as the patho-
metabolically related parameters of blood pressure. Eight of these ten positive outcomes were 
from the 12 C. cassia studies (Akilen et al., 2010; Blevins et al., 2007; Crawford, 2009; 
Gullapalli et al., 2013; Hasanzade et al., 2013; Khan et al., 2003; Lu et al., 2012; Mang et al., 
2006; Sengsuk et al., 2016; Soni and Bhatnagar, 2009; Suppapitiporn et al., 2006; 
Vanschoonbeek et al., 2006) and the remaining positive outcomes were two of the three C. 
verum studies (Azimi et al., 2014; Vafa et al., 2012). Furthermore, C. cassia 1.5-6g per day, 
aqueous extract 120-360 mg per day for 40 days – three months, or C. verum 3g per day for 
eight weeks reduced triglyceride and LDL levels in T2DM patients (Khan et al., 2003; Lu et 
al., 2012; Sengsuk et al., 2016). Considering that body fat is a significant diabetes-associated 
risk factor for cardiovascular disease (Howard et al., 2000), C. cassia and C. verum may help 
prevent the development of vascular comorbidity in T2DM.  Five studies (Azimi et al., 2016; 
Blevins et al., 2007; Hasanzade et al., 2013; Suppapitiporn et al., 2006; Vanschoonbeek et al., 
2006) reported no improvements in the analysed outcome measures including fasting glucose 
levels and HbA1c.  Four of these were C. cassia studies (Blevins et al., 2007; Hasanzade et 
al., 2013; Suppapitiporn et al., 2006; Vanschoonbeek et al., 2006) and one was a C. verum 
study (Azimi et al., 2016). The dosages for three of C. cassia studies were 1g per day 









Vanschoonbeek et al., 2006).  These dosages are low compared to the most commonly used 
dosage of 3g per day. In addition, the duration in the Hasanzade study was 30 days 
(Hasanzade et al., 2013), which is likely too short to meaningfully assess changes in HbA1c 
levels, an outcome measure used in the study. Administration of 3g per day for eight weeks 
showed no improvement in a study (Azimi et al., 2016), which measured blood pressure and 
endothelial function in T2DM rather than direct blood glucose parameters. This is relevant 
considering the relationship between poor blood glucose control and hypertension via the 
development of atherosclerosis may take longer to modify than eight weeks that was provided 
in the trial. Interestingly, when the same authors reported fasting blood glucose as the 
outcome measure on this study, a decrease was found (Azimi et al., 2014), suggesting it is 
easier to modify this parameter with C. verum than its downstream effects. Both publications 
(Azimi et al., 2014; Azimi et al., 2016) refer to different datasets within the same study of 
four individual herbal interventions, including C. verum 3g/day.  
 
3.1.2 Related Clinical Conditions: C. cassia and C. verum compared (Table 2-2)  
Four studies were conducted on subjects with clinical conditions other than T2DM: 
IGT (Wickenberg et al., 2012; Wickenberg et al., 2014) as a pre-diabetic condition,  and 
obesity (Gutierrez et al., 2016; Magistrelli and Chezem, 2012), which is a risk factor for 
diabetes.  In obese subjects, ingestion of C. cassia 5g and 6g suppressed postprandial glucose 
rise (Gutierrez et al., 2016; Magistrelli and Chezem, 2012).. In a study with IGT participants, 
Wickenberg et al. found no impact of C. cassia 12g per day for 12 weeks on the fasting 
glucose and insulin levels (Wickenberg et al., 2014). These findings suggest the potential 
effectiveness of C. cassia at 5g-6g per day, but not as high as 12g per day for the prevention 
of T2DM development in individuals with high risk. 
Turning to C. verum, Wickenberg also authored a study on C. verum, and found no 
effect of C. verum 6g on postprandial blood glucose and insulin levels (Wickenberg et al., 










3.1.3 Healthy: C. cassia and C. verum compared (Table 2-3)  
A study on healthy subjects found that postprandial insulin rise was suppressed by 3g C. 
cassia but not by 1g (Hlebowicz et al., 2009), suggesting that the critical dosage of C. cassia 
lies between 1 and 3 g per day. Single administration of C. cassia (3g or 5g) (Hlebowicz et 
al., 2009; Solomon and Blannin, 2007) and C. cassia (3g) for 14 days (Solomon and Blannin, 
2009) led to decrease in postprandial glucose response. Mettler et al. reported that C. cassia 
4g had a significant impact on postprandial glucose levels only when taken in combination 
with acetic acid (Mettler et al., 2009). Interestingly, in the historical text ‘Le Livre des 
Simples Medecines’, combination of cinnamon with vinegar is suggested for its effectiveness 
(Nam, 2014). These data suggest that C. cassia powder 3g or C. cassia taken with vinegar, 
could help control blood glucose levels and associated parameters, which may be of benefit to 
T2DM patients.  
In two C. verum studies in healthy populations, ingestion of an alcoholic extract (1g) 
of C. verum led to a reduction in postprandial glucose and insulin levels (Beejmohun et al., 
2014), while ingestion of a dose of C. verum 3g with a high fat meal (Markey et al., 2011) did 
not influence postprandial changes in glucose and triacylglycerol levels.  
Overall, C. cassia (≥ 3g) in healthy individuals had positive outcomes in postprandial 
glucose control, while evidence supporting C. verum is insufficient. 
 
3.2 Safety issues 
3.2.1 Adverse events in the clinical trials 
Ten studies positively reported no adverse events.  Fourteen studies did not report whether or 
not any adverse events occurred during the studies.  One study reported a subject developing 
a rash (Crawford, 2009).  Another study (Wickenberg et al., 2014), using 12g/day C .cassia 
for 12 weeks, whilst not actively reporting adverse events, did measure liver enzymes, and 
found no change in serum transaminases. 
 









Due to the high coumarin content of C. cassia, C. verum has been suggested to be a safe 
alternative intervention for diabetes (Medagama, 2015). Coumarin (2H-chromen-2-one) is a 
naturally occurring constituent of many plants, and long term use of cinnamon as a flavouring 
agent is generally considered safe (Leach and Kumar, 2012).  It was first isolated from tonga 
beans Dipteryx odorata (Aubl.) Willd. in 1820 and chemically synthesized coumarin had 
been marketed as a food flavouring agent for a long time until its hepatotoxic potential was 
discovered in laboratory animals in the middle of the 20th century. From the 1970s, coumarin 
was approved as a medicine to treat oedemas as well as tumours in several countries. 
However some patients developed severe hepatotoxicity, which led to the withdrawal of 
products from the market in 1990s (Abraham et al., 2010). Coumarin is metabolized via two 
major pathways: detoxification by 7-hydroxylation and the formation of 3,4-epoxide 
intermediate, the latter of which leads to the generation of a hepatotoxic metabolite o-HPA. 
As the 7-hydroxyation pathway is predominant in primates including humans, humans are 
less susceptible to coumarin hepatotoxicity compared to rodents. However, clinical data 
revealed that a human population subgroup reacts sensitively to coumarin (Loprinzi et al., 
1999; Schmeck-Lindenau et al., 2003), although the underlying mechanism is unknown 
(Abraham et al., 2010).  
 To evaluate the coumarin-related safety issues of the two cinnamon species, database 
searches were conducted. The search retrieved a total of 19 results (18 results for PubMed, 1 
for ScienceDirect), of which five articles are selected and summarised in Table 3. Abraham et 
al. (2011) compared the absorption of coumarin after oral administration of isolated coumarin 
and C. cassia in different preparations (capsules, tea, and rice pudding) (Abraham et al., 
2011). They found that coumarin in isolation and in C. cassia were equally absorbed, and that 
C. cassia tea exhibited the fastest and highest coumarin absorption, compared to capsules and 
rice pudding. Data on the coumarin contents in different cinnamon species confirmed higher 
coumarin levels in C. cassia compared to C. verum (Table 3). Three independent studies 
conducted on the coumarin levels of C. cassia reported considerably different values: 









(Wang et al., 2013), and 1.60±1.70g/kg (0.33-6.5 g/kg) (Lv et al., 2010), which could be due 
to several factors including extraction methods, analytical methods, and the sources of plant 
materials. In fact, those studies were conducted using different extraction and analytical 
methods, namely 80% methanol extraction without heat or sonication and LC-MS and DIP-
APCI-MS analyses (Krieger et al., 2013), methanol extraction with sonication and UPLC-
UV/MS (Wang et al., 2013), and pressurized liquid extraction with ethyl acetate at 160°C and 
and GC-MS (Lv et al., 2010), which could underlie the variability in these studies. 
Furthermore, plant materials were obtained from different sources, such as German retail 
market (Krieger et al., 2013), commercial source in China and the United States (Wang et al., 
2013), and different regions of China (Lv et al., 2010). As demonstrated by Lv et al., 
coumarin contents of C. cassia could considerably vary (from 0.33 to 6.50 mg/g) depending 
on the geographical origins (Lv et al., 2010), which is likely due to different climatic 
conditions, plant age, and harvest timings. In addition, coumarin levels could vary depending 
on which plant parts were used. A study compared the levels of coumarin and other 
constituents in the bark, shaved bark (without cork layer), and twig of C. cassia, both used in 
traditional East Asian medicines, and found that coumarin in cinnamon twig was less than 
one-third compared to cinnamon bark, and shaved cinmmamon bark contained the highest 
levels of coumarin (Chen et al., 2016). Importantly, a study showed that a de-coumarinated 
polyphenol-enriched C. cassia extract, prepared using a novel procedure, was effective in 
lowering blood glucose levels in T2DM rats (IM et al., 2014a), indicating that the selection of 
extraction procedure could significantly enhance the safety of C. cassia. Of note, C. 
burmannii (Nees & T. Nees) Blume, commonly also known as ‘cassia’ cinnamon (Avula et 
al., 2015), has characteristically high coumarin levels, which is distinct from C. cassia (Avula 
et al., 2015; Chen et al., 2014; Wang et al., 2013), and C. burmannii was likely referred to as 
‘cassia’ cinnamon in some reports. Importantly, Wang et al. reported that C. cassia contains 
higher levels of cinnamaldehyde: C. cassia (18.5±2.9 g/kg, n=4) > C. verum (11.2±5.5 g/kg, 
n=17) (Wang et al., 2013). Considering that anti-diabetic actions of cinnamon is at least partly 








considered as a replacement for C. cassia. In fact, short-term administration ( 14days) of C. 
verum (3g and 6g) were ineffective (Markey et al., 2011; Wickenberg et al., 2012), while C. 
cassia 3 - 6 g were effective (Hlebowicz et al., 2009; Magistrelli and Chezem, 2012; Mettler 
et al., 2009; Solomon and Blannin, 2007), suggesting that C. cassia has higher potency 
compared to C. verum. Overall, it is important to identify botanical origin, geographical 
origin, plant parts, and extraction procedures, in using and reporting analytical as well as 
clinical trial data. 
In addition to liver damage caused by coumarin, allergic reactions should be 
considered as a possible adverse effect, as several cases of contact dermatitis have been 
reported (Ackermann et al., 2009; Calapai et al., 2014; Isaac-Renton et al., 2015). In fact, a 
subject developed a rash after consuming C. cassia 1g per day in a trial (Crawford, 2009), 
however this was the only adverse reaction reported in any of the trials considered in this 
review. In fact, no case reports of interactions were identified therefore it was considered 
unlikely that it would affect the effectiveness of conventional drugs (Edwards et al., 2015). 
However, pharmacovigilance is important for any potential interactions and additive effects.   
Both C. verum and C. cassia, in therapeutic doses, should be avoided during pregnancy 
(Edwards et al., 2015; Gardner and McGuffin, 2013). 
 
3.3 Limitation of the study 
Due to the scarcity of available data, this study included both randomised placebo-controlled 
and open-label trials. In addition, compared to C. cassia, only a few trials have been 
conducted with C. verum. This is limiting as the discussion is  based on evidence supported 
by a small number of studies with less vigorous study designs. More robust studies are needed 
in the future. 
 









Most clinical studies were conducted using C. cassia, which was originally used as an anti-
diabetic medicine and listed as the unique origin of ‘Cortex cinnamomi’ in the Chinese 
pharmacopoeia (Lv et al., 2010). Evidence suggests that oral administration of C. cassia 3-6g 
per day could improve glucose metabolism in T2DM patients and healthy individuals, while 
effectiveness was inconsistent below 1.5g. However, heterogeneity in the methods used in the 
trials as well as quality issues including lack of botanical authentication compromise the 
evidence for the efficacy and safety.  
 Therapeutic potency depends on the levels of active constituents. Considering that 
medicinal plants in general contain a number of bioactive compounds, the levels of which 
could be affected by many factors such as geographical origin, plant parts, and crude drug 
processing, it is important to assess the chemical properties of botanical medicines before 
using and evaluating the therapeutic potency and safety. In addition, due to the high coumarin 
content of C. cassia, future trials should be designed taking into account the assessment of 
potential hepatotoxicity by including liver function tests over suitable trial durations. These 
efforts would allow a more reliable safety and efficacy evaluation of C. cassia. as a diabetes 
intervention.  
 On the other hand, data are scarce and inconclusive for the effectiveness of C. verum. 
It should be noted that the interchangeability of the two cinnamon species as a diabetes 
intervention is not established and there is currently no standardisation method for quality 
control. It is important for practitioners to consider possible differences in the potency 
between the two species as well as within the same species, and potential risk associated with 
coumarin consumption. Given the low coumarin content of C. verum there is an opportunity 
for more robust RCTs, of longer duration and larger participant numbers giving greater 
power, to investigate whether this species has potential for this growing patient group. The 
effective and safe dosage practices for different species should be built on scientific data 
through careful examination and comparison, as well as drawing on long-standing traditional 
usages. Key to this is clarity about the intervention including establishing botanical 









diabetic, but also the growing number of diseases that are related to insulin resistance, and 
hence favourably ameliorate the personal, social and economic costs of these conditions. 
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Records identified through 
database searching 




























Records after duplicates removed 
(n = 191) 
Records screened 
(n = 191) 
Records excluded 
(n = 159) 
Full-text articles assessed 
for eligibility 
(n =32) 
Full-text articles excluded, 
with reasons 
(3 unspecified spp, 3 
different spp. C. burmanii 
and one combination 
product with zinc) 
(n = 7) Studies included in 
qualitative synthesis 









Table 1. Trials included in five previous reviews and current study 
 Previous reviews 
Current study 









11 trials but 
16 datasets 




Number of trials 6 10 10 11 8 25 
C. cassia 
T2DM 
Khan et al. (2003)  √ √ √  √ √ 
Mang et al. (2006) √ √ √ √ √ √ 
Suppapitiporn et al.  (2006)  √ √ √ √ √ 
Vanschoonbeek et al. (2006) √ √ √ √ √ √ 
Blevins et al. (2007) √ √ √ √ √ √ 
Crawford (2009) √ √ √ √ √ √ 
Akilen et al. (2010) √ √ √ √ √ √ 
Lu et al. (2012)    √ √  √ 
Hasanzade et al. (2013)    √  √ 
Gullapalli et al. (2013)    √  √ 
Sengsuk et al. (2015)      √ 
Soni and Bhatnagar (2009)       √ 
Related clinical conditions 
Magistrelli & Chezem 
(2012) 
     
√ 
Wickenberg et al. (2014)      √ 
Gutierrez et al. (2016)      √ 
Healthy 
Solomon & Blannin (2007)       √ 
Hlebowicz et al. (2009)       √ 
Solomon & Blannin (2009)      √ 
Mettler et al. (2009)      √ 
C. verum 
T2DM 
Vafa et al. (2012)    √  √ 
Azimi et al. (2014)      √ 
Azimi et al. (2016)      √ 
Related clinical conditions 
Wickenberg et al. (2012)      √ 
Healthy 
Beejmohun et al. (2014)       √ 
Markey et al. (2011)        √ 
Not C. cassia / C. verum, unidentified species or combined with other substances 
Altschuler et al. (2007)   √     
Khan et al.  (2010)   √ √    
Rosado et al. (2010)  √     
Wainstein et al. (2011)   √ √   





































































Table 2-1. Trials with T2DM patients 
1st Author Population Intervention Source of 
cinnamon bark 










Sample size: n=99 
(treatment: 49, 
control: 50) 
C. cassia 1.5g per 
day (after each 
meal, 0.5g each), 




























Sample size: n = 60 
(treatment: 30, 
control: 30) 
C. cassia 1g, 3g or 

































Sample size: n= 71 
(treatment: 35, 
control: 36) 
C. cassia 1g per 
day (after 
breakfast and 
dinner 0.5g each), 











Control: placebo  
No significant 
effect on fasting 









Lu et al. 
(2012) 
Population: Chinese 
patients with T2DM, 
taking sulfonylurea, 
aged around 60 
Sample size: n=66 
(placebo: 20, low-
dose: 23, high-dose: 
23) 
C. cassia aqueous 
extract 120 mg 
(from 2.8g of C. 
cassia) or 360 mg 


































Sample size: n=58 
(treatment: 30, 
control: 28) 
C. cassia 2g per 






















ethnic, aged around 
60 
Sample size: n=109 
(treatment: 55, 
control: 54) 
C. cassia 1g each 
day with meal, for 









management care  
Significant 
reduction in 





















male patients aged 
40-60 
Sample size: n=30 
(treatment: 15, 
control: 15) 
C. cassia 2g per 
day (after 
breakfast, lunch, 
evening tea, and 
dinner, a quarter 
each), for 40 days 





















Sample size: n=57 
(treatment: 29, 
control: 28) 
C. cassia 1g per 
day (2x 0.5g 
capsules, one with 
breakfast one with 
dinner), for 3 
months 








No effect on 
fasting glucose, 


















Sample size: n = 60 
(treatment: 20; 
control 40) 
C. cassia 1.5g per 
day, for 12 weeks.  
No information Study design:  
randomized, 
single blind  
No decrease in 
HbA1c, lipid 
profile, fasting 
















 Reduction in 
SGOT (AST).  
unknown
. 
Mang et al. 
(2006) 
Population:  T2DM 
patients (not on 
insulin therapy), 
aged 31.1±2.0 
Sample size: n=65 
(treatment: 33, 
control: 32) 
C. cassia aqueous 
extract 336mg 
(equivalent to 3g 
of C.cassia) daily 
(capsules 1g x 3 



























patients with T2DM, 
aged 62.9±1.5. 
Sample size: n=25 
(treatment: 13, 
control: 12) 
C. cassia 1.5g per 
day (0.5g x 3 
times a day after 
each meal), for 2 
and 6 weeks 











levels, at 2 weeks 
















average age 52.0 
Sample size: n=30 
(10 per group) 
C. cassia 1g, 3g, 
or 6g per day, 
after lunch and 
dinner, for 40 
days 
Certified by the 



















levels, at 20, 40, 


















Sample size: n=79 
(treatment: 40, 
control: 39) 
C. verum 3g with 
black tea for 8 
weeks 
Approved by 







Control: black tea 
only  




















C. verum 3g with 
black tea, for 8 
weeks 
Approved by 













No effect insulin 
and HbA1c but 












patients, sample size: 





C. verum 3g per 
day for 8 weeks 










weight, BMI and 














Table 2-2. Trials with related clinical conditions 
1st Author Population Intervention Source of 
cinnamon 
bark 







sedentary and obese 
females aged 22.7±4 
Sample size: n=10 











Lower response to 
oral glucose 











g, J. et al. 
(2014) 
Population: IGT, 
aged around 72 
Sample size: n=17 
(treatment: 8, 
control: 9) 
12g C. cassia 
per day, for 









































(BMI 21.1±1.1, aged 
21.0±2.5)  
and obese (BMI 
33.1±4.6, aged 
22.1±2.4) 
Sample size: n=45 





































Sample size:  
n=10 
 




































Table 2-3. Trials with healthy populations 
















mixed with 1 or 















rise. Increase in the 
release of glucagon 
like peptide 1 (GLP-
1) (3g C. cassia 












Sugar drink and 
milk rice meal 
with: 
1. C.cassia 4g 
in the meal 
2. vinegar in the 
sugar drink 















drink and plain 
milk rice meal 
(1) No difference for 
C.cassia alone. (2) 
Postprandial glucose 
levels lower for 















C. cassia 3g per 





































































glucose. Increase in 
insulin sensitivity by 
one index (Matsuda) 





















































A high-fat meal, 
with C. verum 
















function, or appetite, 
in response to a 
























Source of plant 
materials 
Coumarin levels  
Krieger et al. 
(2013) 
Methodological 





C. verum and C. 
cassia powder 
from different 
origins (n=5 for 
C. verum and n=2 













C. cassia contains 
considerably higher 
levels of coumarin. 
No information 
Wang et al. 
(2013) 






containing foods and 
supplements 
C. verum, C. 
cassia, C. 
loureiroi, and C. 
burmannii from 
different origins 
(n=16 for C. 
verum; n=3 for C. 
cassia; n=1 for C. 



















burmannii > C. 
loureiroi > C. cassia 
> C. verum  
(2) Cinnamon 
aldehyde contents: 






C. verum 3997, 
3974 - 3987, 













To determine the 
coumarin content of 
ground cinnamon in 







Hot water  
Analysis: 
HPLC-UV 






Lv et al. 
(2010) 
To develop a 
reliable 
quantification 
method for the 
constituents in 
cinnamon 










0.33 – 6.50 g/kg 
(1.70 ± 0.44 
g/kg, n=15) 
C. cassia contains 
cinnamaldehyde: 
16.11 – 38.61 g/kg 







local herbal drug 
stores in 
different parts of 
China (deposited 
at the Institute of 
Chinese Medical 
Sciences, 
University of 
Macau, Macao, 
China).  
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